A European Medicines Agency (EMA) committee recommended that Darzalex (daratumumab) given as an under-the-skin injection be approved for people with smoldering multiple myeloma (SMM)…
News
The U.S. Food and Drug Administration (FDA) has approved a tablet formulation of Beone Medicines’ Brukinsa (zanubrutinib) — previously marketed by the developer in…
Most people with advanced pancreatic cancer who received first-line treatment with atebimetinib were alive and free from disease progression six months after starting treatment,…
A Phase 3 clinical trial of Enhertu, a therapy developed by Daiichi Sankyo and AstraZeneca, has begun dosing its first patient with…
Most people with hard-to-treat multiple myeloma who were given a combination treatment of Talvey (talquetamab-tgvs) and Tecvayli (teclistamab-cqyv) in a clinical trial were alive…
Nearly 1 in 4 people with NPM1-mutated acute myeloid leukemia (AML) achieved complete remission after treatment with ziftomenib in a Phase 2 clinical trial. Dubbed…
Actuate Therapeutics’ treatment candidate elraglusib significantly lowered the risk of death — about doubling one-year survival rates — among people with an advanced form…
A young girl with an unusual form of low-grade glioma, a type of brain tumor, responded well to standard chemotherapy, emphasizing the value of…
Relacorilant lowered the risk of disease progression and death by about 30% when used on top of standard chemotherapy in people with platinum-resistant ovarian cancer.
One-third of patients with hard-to-treat myeloma were alive and free from disease progression five years after a single infusion of the cell therapy Carvykti…
